Skip to main content
. 2014 Nov 19;14:848. doi: 10.1186/1471-2407-14-848

Figure 1.

Figure 1

MUC1 and VEGF mRNA levels in blood of NSCLC patients. (A and B) Box-whisker plots of blood MUC1 mRNA levels in NSCLC patients with progressive disease (PD), stable disease (SD) and partial response (PR) before (B0) and 4 weeks after the start of gefitinib treatment (B4w). (C and D) Box-whisker plots of blood VEGF mRNA levels in NSCLC patients with PD, SD and PR at B0 and B4w.